CNTA Filing Reveals Upcoming $140K Stock Sale by Centessa Insider
Rhea-AI Filing Summary
Centessa Pharmaceuticals (NASDAQ: CNTA) submitted a Form 144 notice covering the proposed sale of 10,000 common shares—approximately $140,000 in aggregate market value—through UBS Financial Services on or around 26 June 2025. The filing lists 133,618,774 shares outstanding, so the planned sale represents less than 0.01 % of the float.
The same account holder reported three earlier open‐market sales during the past three months: 10,000 shares on 25 March 2025 for $163,386, 11,742 shares on 25 April 2025 for $159,857, and 10,000 shares on 27 May 2025 for $128,225. Combined with the new notice, gross proceeds from the four transactions total roughly $591,000. No additional financial statements, risk factors, or business updates were provided in this routine disclosure.
Positive
- None.
Negative
- None.